Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP24A1 | Q07973 | 6/20 | 0.60 |
| ▸ | CYP27A1 | Q02318 | 3/20 | 0.60 |
| ▸ | CYP19A1 | P11511 | 5/20 | 0.60 |
| ▸ | CYP26A1 | O43174 | 3/20 | 0.59 |
| ▸ | DRD2 | P14416 | 2/20 | 0.54 |
| ▸ | HTR2A | P28223 | 2/20 | 0.54 |
| ▸ | HTR2C | P28335 | 2/20 | 0.54 |
| ▸ | HTR2B | P41595 | 2/20 | 0.54 |
| ▸ | SIGMAR1 | Q99720 | 2/20 | 0.54 |
| ▸ | MIF | P14174 | 1/20 | 0.50 |
| ▸ | MAOB | P27338 | 1/20 | 0.47 |
| ▸ | SLC6A2 | P23975 | 1/20 | 0.47 |
| ▸ | SLC6A4 | P31645 | 1/20 | 0.47 |
| ▸ | SLC6A3 | Q01959 | 1/20 | 0.47 |
| ▸ | MAPK14 | Q16539 | 1/20 | 0.46 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.46 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.46 |
| ▸ | LMNA | P02545 | 1/20 | 0.46 |
| ▸ | GAA | P10253 | 1/20 | 0.46 |
| ▸ | MAPT | P10636 | 1/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL15874767 | 1.00 | CYP24A1 (0.60) | CYP24A1CYP27A1CYP19A1CYP26A1DRD2 | |
| SCHEMBL5077391 | 0.92 | CYP19A1 (0.57) | CYP24A1CYP27A1CYP19A1CYP26A1DRD2 | |
| SCHEMBL6669546 | 0.92 | CYP24A1 (0.53) | CYP24A1CYP27A1CYP19A1CYP26A1DRD2 | |
| SCHEMBL4602048 | 0.90 | DDB1 (0.56) | CYP24A1CYP27A1CYP19A1CYP26A1DRD2 | |
| SCHEMBL10593732 | 0.86 | CYP24A1 (0.52) | CYP24A1CYP27A1CYP19A1CYP26A1DRD2 | |
| SCHEMBL10596034 | 0.86 | CYP24A1 (0.52) | CYP24A1CYP27A1CYP19A1CYP26A1DRD2 | |
| SCHEMBL9146594 | 0.86 | CYP19A1 (0.63) | CYP24A1CYP27A1CYP19A1CYP26A1DRD2 | |
| SCHEMBL8870256 | 0.85 | CYP19A1 (0.60) | CYP24A1CYP27A1CYP19A1CYP26A1DRD2 | |
| SCHEMBL22628673 | 0.84 | CYP24A1 (0.47) | CYP24A1CYP27A1CYP19A1CYP26A1DRD2 | |
| SCHEMBL10597721 | 0.84 | CYP24A1 (0.47) | CYP24A1CYP27A1CYP19A1CYP26A1MIF |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 40 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-119161384-A | Estrogen receptor modulating compounds | 雷迪厄斯制药公司 | 2024-12-20 | — | — | CN | disclosed |
| CN-112105607-B | Estrogen receptor modulating compounds | 雷迪厄斯制药公司 | 2024-08-27 | — | — | CN | disclosed |
| US-12018019-B2 | Estrogen receptor-modulating compounds | RADIUS PHARMACEUTICALS, INC. (US) | 2024-06-25 | — | — | US | disclosed |
| US-11384068-B2 | Estrogen receptor-modulating compounds | RADIUS PHARMACEUTICALS, INC. (US) | 2022-07-12 | — | — | US | disclosed |
| US-20200347032-A1 | ESTROGEN RECEPTOR-MODULATING COMPOUNDS | RADIUS HEALTH, INC. | 2020-11-05 | — | — | US | disclosed |
| US-10399939-B2 | Tetrahydronaphthalene estrogen receptor modulators and uses thereof | GENENTECH, INC. (US) | 2019-09-03 | — | — | US | disclosed |
| US-10399939-B2 | Tetrahydronaphthalene estrogen receptor modulators and uses thereof | GENENTECH, INC. (US) | 2019-09-03 | — | — | US | disclosed |
| EP-3374356-A1 | TETRAHYDRONAPHTHALENE ESTROGEN RECEPTOR MODULATORS AND USES THEREOF | H. Hoffnabb-La Roche Ag (CH) | 2018-09-19 | — | — | EP | disclosed |
| WO-2017080966-A1 | TETRAHYDRONAPHTHALENE ESTROGEN RECEPTOR MODULATORS AND USES THEREOF | F. HOFFMANN-LA ROCHE AG (CH) | 2017-05-18 | — | — | WO | disclosed |
| WO-2017080966-A1 | TETRAHYDRONAPHTHALENE ESTROGEN RECEPTOR MODULATORS AND USES THEREOF | F. HOFFMANN-LA ROCHE AG (CH) | 2017-05-18 | — | — | WO | disclosed |
| US-7425568-B2 | Compounds, which are potent inhibitors of Na+ /Ca2+ exchange mechanism and are useful in the treatment of arrhythmias | ORION CORPORATION (FI) | 2008-09-16 | — | — | US | disclosed |
| US-20060241147-A1 | Pyridine derivatives useful for inhibiting sodium/calcium exchange system | ORION CORPORATION (FI) | 2006-10-26 | — | — | US | disclosed |
| EP-1412343-B1 | COMPOUNDS, WHICH ARE POTENT INHIBITORS OF NA+/CA2+ EXCHANGE MECHANISM AND ARE USEFUL IN THE TREATMENT OF ARRHYTHMIAS | ORION CORP (FI) | 2006-08-30 | — | — | EP | disclosed |
| EP-1583759-A1 | PYRIDINE DERIVATIVES USEFUL FOR INHIBITING SODIUM/CALCIUM EXCHANGE SYSTEM | ORION CORPORATION (FI) | 2005-10-12 | — | — | EP | disclosed |
| US-20040235905-A1 | Compounds, which are potent inhibitors of na+ / ca2+ exchange mechanism and are useful in the treatment of arrhythmias | ORION CORPORATION (FI) | 2004-11-25 | — | — | US | disclosed |
| WO-2004063191-A1 | PYRIDINE DERIVATIVES USEFUL FOR INHIBITING SODIUM/CALCIUM EXCHANGE SYSTEM | ORION CORPORATION (FI) | 2004-07-29 | — | — | WO | disclosed |
| EP-1412343-A1 | NEW COMPOUNDS, WHICH ARE POTENT INHIBITORS OF NA+/CA2+ EXCHANGE MECHANISM AND ARE USEFUL IN THE TREATMENT OF ARRHYTHMIAS | ORION CORPORATION (FI) | 2004-04-28 | — | — | EP | disclosed |
| WO-2003006452-A1 | NEW COMPOUNDS, WHICH ARE POTENT INHIBITORS OF NA+/CA2+ EXCHANGE MECHANISM AND ARE USEFUL IN THE TREATMENT OF ARRHYTHMIAS | ORION CORPORATION (FI) | 2003-01-23 | — | — | WO | disclosed |
| EP-0163416-B1 | PHENOL DERIVATIVES | IMPERIAL CHEMICAL INDUSTRIES PLC (GB) | 1989-05-31 | — | — | EP | disclosed |
| US-4751240-A | ANTIFERTILITY AGENTS | IMPERIAL CHEMICAL INDUSTRIES PLC (GB) | 1988-06-14 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20200347032-A1 | ESTROGEN RECEPTOR-MODULATING COMPOUNDS | ESR2, GPER1, ESR1 | CYP24A1 117/4885CYP27A1 232/4885CYP19A1 15/4885 |
| US-20040235905-A1 | Compounds, which are potent inhibitors of na+ / ca2+ exchange mechanism and are useful in the treatment of arrhythmias | CACNA1E, KCNN4, RYR2 | CYP24A1 626/4885CYP27A1 412/4885CYP19A1 2036/4885 |
| US-11384068-B2 | Estrogen receptor-modulating compounds | ESR2, GPER1, ESR1 | CYP24A1 117/4885CYP27A1 232/4885CYP19A1 15/4885 |
| US-12018019-B2 | Estrogen receptor-modulating compounds | ESR2, GPER1, ESR1 | CYP24A1 117/4885CYP27A1 232/4885CYP19A1 15/4885 |
| US-10399939-B2 | Tetrahydronaphthalene estrogen receptor modulators and uses thereof | GPER1, ESR2, ESR1 | CYP24A1 95/4885CYP27A1 93/4885CYP19A1 8/4885 |
| US-20060241147-A1 | Pyridine derivatives useful for inhibiting sodium/calcium exchange system | SLC8B1, CACNA1A, MCU | CYP24A1 343/4885CYP27A1 274/4885CYP19A1 2119/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.